Skip to content
Recall Observatory FDA recall evidence

Drug product

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China

D-0379-2026

February 13, 2026

Class II

Product summary

Firm
Harbin Jixianglong Biotech Co., Ltd.
Event
Event 98438
Status
Ongoing
Classification
Class II
Quantity
N/A
Official record key
drug-enforcement:D-0379-2026

Official wording

Reason: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Code information: Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027

Distribution pattern: Nationwide within the United States

Derived failure modes

  • Manufacturing or process control

    reason.manufacturing_process_control · v1.0.0

    CGMP Deviations